ABBOTT-LEVETIRACETAM TABLET

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

LEVETIRACETAM

Доступна с:

ABBOTT LABORATORIES, LIMITED

код АТС:

N03AX14

ИНН (Международная Имя):

LEVETIRACETAM

дозировка:

500MG

Фармацевтическая форма:

TABLET

состав:

LEVETIRACETAM 500MG

Администрация маршрут:

ORAL

Штук в упаковке:

100

Тип рецепта:

Prescription

Терапевтические области:

MISCELLANEOUS ANTICONVULSANTS

Обзор продуктов:

Active ingredient group (AIG) number: 0148843002; AHFS:

Статус Авторизация:

CANCELLED POST MARKET

Дата Авторизация:

2015-12-31

Характеристики продукта

_ _
_Abbott-Levetiracetam Product Monograph _
_Page 1 of 33_
PRODUCT MONOGRAPH
PR
ABBOTT-LEVETIRACETAM
Levetiracetam Tablets USP
250 mg, 500 mg and 750 mg
Antiepileptic Agent
Abbott Laboratories, Limited
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
Control No.: 183151
Date of Preparation:
November 1, 2013
Date of Revision:
March 27, 2015
_ _
_Abbott-Levetiracetam Product Monograph _
_Page 2 of 33 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
................................................................................................11
DOSAGE AND ADMINISTRATION
..............................................................................13
OVERDOSAGE
................................................................................................................15
ACTION AND CLINICAL PHARMACOLOGY
............................................................15
STORAGE AND STABILITY
..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
...............................................................................20
PHARMACEUTICAL INFORMATION
..........................................................................20
CLINICAL TRIALS
............................................................................